Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 27 2023 - 4:05PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced Lauren Sabella has joined the
company as Executive Vice President, Chief Operating Officer,
effective today. Sabella will report directly to Michael Castagna,
PharmD, Chief Executive Officer, and serve on the company’s
executive leadership team.
“Lauren is an inspirational leader, and we are delighted to
welcome her to MannKind at a pivotal time,” said Dr. Castagna.
“Lauren will be leading all our critical functions that operate in
Danbury, focused on growing our endocrine business and preparing to
launch our emerging pipeline in the orphan lung area.”
Sabella brings deep commercial, respiratory, and operational
experience to MannKind with a career that has spanned small-cap to
large-cap pharmaceutical companies. Prior to MannKind, she was at
Acorda Therapeutics for 12 years. Her last role was Chief Operating
Officer, where she had responsibility for overall business
operations including quality, medical affairs, regulatory,
technical operations, information technology, project management,
and pharmaceutical development departments as well as the strategic
planning function for the organization. Prior to that role, Sabella
was Acorda’s Chief Commercial Officer and launched their flagship
product Ampyra® for multiple sclerosis whose peak sales exceeded
half a billion dollars. Earlier in her career, she was Vice
President of Commercial Development at Altus Pharmaceuticals with
responsibility for all aspects of commercialization. Sabella also
spent 18 years at Boehringer Ingelheim Pharmaceuticals in positions
of increasing responsibility, which included over 10 years of
marketing experience and an impressive accomplishment of two
product launches that surpassed $1 billion in sales. A graduate of
Hofstra University, Sabella will be based in Danbury.
“I am honored and excited to be joining MannKind as it continues
to scale and execute its plan to help people living with endocrine
and orphan lung diseases,” said Sabella. “I am energized to work
with this innovative team as we drive operational excellence in an
action-driven environment.”
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking StatementsThis press release
contains forward-looking statements about growth plans and
potential product launches that involve risks and uncertainties.
Words such as “believes”, “anticipates”, “plans”, “expects”,
“intends”, “will”, “goal”, “potential” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon MannKind’s current
expectations. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that the products we are
commercializing may only achieve a limited degree of commercial
success, the need for product candidates to undergo nonclinical and
clinical testing and obtain regulatory approval prior to their sale
and marketing, and other risks detailed in MannKind’s filings with
the Securities and Exchange Commission, including its Annual Report
on Form 10-K for the year ended December 31, 2022, and subsequent
periodic reports on Form 10-Q and current reports on Form 8-K. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
MANNKIND is a registered trademark of MannKind Corporation.
For MannKind:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024